204 related articles for article (PubMed ID: 29322659)
41. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
Carroll KJ
J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
[TBL] [Abstract][Full Text] [Related]
42. How Well Are We Applying Quantitative Methods to Reverse Translation to Inform Early Clinical Development?
Heatherington AC; Kasichayanula S; Venkatakrishnan K
Clin Pharmacol Ther; 2018 Feb; 103(2):174-176. PubMed ID: 29274086
[TBL] [Abstract][Full Text] [Related]
43. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
[TBL] [Abstract][Full Text] [Related]
44. Model-based drug development: a rational approach to efficiently accelerate drug development.
Milligan PA; Brown MJ; Marchant B; Martin SW; van der Graaf PH; Benson N; Nucci G; Nichols DJ; Boyd RA; Mandema JW; Krishnaswami S; Zwillich S; Gruben D; Anziano RJ; Stock TC; Lalonde RL
Clin Pharmacol Ther; 2013 Jun; 93(6):502-14. PubMed ID: 23588322
[TBL] [Abstract][Full Text] [Related]
45. Naloxegol (Movantik) for opioid-induced constipation.
Med Lett Drugs Ther; 2015 Sep; 57(1478):135-7. PubMed ID: 26393826
[No Abstract] [Full Text] [Related]
46. Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives.
Donelan R; Walker S; Salek S
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):319-28. PubMed ID: 25628072
[TBL] [Abstract][Full Text] [Related]
47. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
Nikolakopoulos S; van der Wal WM; Roes KC
J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
[TBL] [Abstract][Full Text] [Related]
48. Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPD.
Di Scala L; Kerman J; Neuenschwander B
Stat Med; 2013 May; 32(10):1621-34. PubMed ID: 23303622
[TBL] [Abstract][Full Text] [Related]
49. Leveraging model-informed approaches for drug discovery and development in the cardiovascular space.
Dockendorf MF; Vargo RC; Gheyas F; Chain ASY; Chatterjee MS; Wenning LA
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):355-364. PubMed ID: 29353335
[TBL] [Abstract][Full Text] [Related]
50. Determination of naloxegol in human biological matrices.
Li Y; Hoffmann M; Severin P
Bioanalysis; 2017 Apr; 9(8):609-619. PubMed ID: 28504549
[TBL] [Abstract][Full Text] [Related]
51. Trial watch: personalized medicines in late-stage development.
Milne CP; Garafalo S; Bryan C; McKiernan M
Nat Rev Drug Discov; 2014 May; 13(5):324-5. PubMed ID: 24781541
[No Abstract] [Full Text] [Related]
52. Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development.
Wessels AM; Edgar CJ; Nathan PJ; Siemers ER; Maruff P; Harrison J
Drug Discov Today; 2021 May; 26(5):1330-1336. PubMed ID: 33486115
[TBL] [Abstract][Full Text] [Related]
53. A modelling framework for improved design and decision-making in drug development.
Wiklund SJ
PLoS One; 2019; 14(8):e0220812. PubMed ID: 31461440
[TBL] [Abstract][Full Text] [Related]
54. Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development.
Gibbs JP; Menon R; Kasichayanula S
Clin Pharmacol Ther; 2018 Feb; 103(2):196-198. PubMed ID: 29105747
[TBL] [Abstract][Full Text] [Related]
55. Treating Opioid-Induced Constipation in Older Adults: New Options.
Sani H; Mahan RJ
Consult Pharm; 2015 Oct; 30(10):612-5. PubMed ID: 26450143
[TBL] [Abstract][Full Text] [Related]
56. The failure to fail smartly.
Galson S; Austin CP; Khandekar E; Hudson LD; DiMasi JA; Califf R; Wagner JA
Nat Rev Drug Discov; 2021 Apr; 20(4):259-260. PubMed ID: 32968225
[No Abstract] [Full Text] [Related]
57. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
Webster L; Tummala R; Diva U; Lappalainen J
J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
[TBL] [Abstract][Full Text] [Related]
58. The impact of data integrity on decision making in early lead discovery.
Beck B; Seeliger D; Kriegl JM
J Comput Aided Mol Des; 2015 Sep; 29(9):911-21. PubMed ID: 26409840
[TBL] [Abstract][Full Text] [Related]
59. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
Pallay A
J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
[TBL] [Abstract][Full Text] [Related]
60. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
Kimani PK; Stallard N; Hutton JL
Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
